Inhibrx Biosciences cash flow statement data for the quarter ended Jun 2026. This cash flow statement covers 12 quarters of results from Jun 2023 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Cash Flow StatementCash Flow | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||
| Net Income | -47.05M | -51.79M | -93.60M | -78.71M | 1,858.01M | -43.86M | -47.87M | -43.31M | -28.65M | -35.26M | -32.83M | -36.65M |
| Depreciation, Depletion & Amortization | ||||||||||||
| Amortization of Deferred ChargesAmort. Deferred Charges | 1.24M | 1.25M | 1.24M | 0.82M | 0.53M | 0.63M | 0.64M | 0.64M | ||||
| Depreciation & Amortization (CF)Dep. & Amort. | 0.30M | 0.30M | 0.30M | 0.36M | 0.48M | 0.76M | 0.69M | 0.68M | 0.66M | 0.58M | 0.56M | 0.52M |
| Share-based CompensationStock Comp. | 6.53M | 6.43M | 6.40M | 46.17M | 2.97M | 2.98M | 2.45M | 2.77M | 3.18M | 2.74M | ||
| Gains from Sales and DivestituresGains Divest | 0.00M | -0.01M | 0.00M | -0.01M | ||||||||
| Other non-cash itemsOther Non-Cash | 0.80M | 0.90M | -0.08M | 1.27M | -2,020.70M | 0.90M | 1.37M | 1.33M | 0.90M | 1.00M | 1.47M | 1.00M |
| Change in Working Capital | ||||||||||||
| Change in ReceivablesChange Receivables | 0.00M | 0.45M | 0.10M | 0.09M | -0.18M | 0.06M | -0.13M | 0.05M | ||||
| Change in Account PayablesChange Payables | -1.59M | 2.91M | 4.05M | 17.42M | -0.45M | -3.12M | -0.35M | -0.60M | -1.52M | -0.83M | ||
| Change in Accured ExpensesChange Accured Exp. | 6.35M | 17.39M | 8.03M | 21.82M | 6.03M | 2.88M | -4.30M | -1.52M | -1.43M | |||
| Change in Other Operating AssetsOther Assets Change | 15.14M | -8.98M | 4.39M | 3.14M | -4.12M | -3.28M | -0.78M | 0.47M | -0.01M | -1.13M | ||
| Change in Other Operating LiabilitiesOther Liabilities Change | -0.59M | -0.48M | -0.50M | -0.51M | -0.34M | -0.07M | -0.17M | -0.37M | -0.52M | -0.54M | ||
| Other Working Capital ChangesOther WC Changes | -15.73M | 8.50M | -4.89M | -3.65M | 3.78M | 3.21M | 0.61M | -0.84M | -0.52M | 0.59M | ||
| Cash from OperationsCash from Ops. | -54.25M | -56.82M | -63.05M | -57.36M | -30.28M | -43.72M | -35.90M | -29.95M | -33.82M | -30.12M | ||
| Investing Activities | ||||||||||||
| Capital ExpendituresCapex | 0.81M | 3.44M | 1.12M | 1.22M | 0.25M | 0.02M | 0.02M | 0.01M | ||||
| Change in Property, Plant and EquipmentChange in PP&E | -0.81M | -3.44M | -1.12M | -1.22M | -0.25M | -0.02M | -0.02M | -0.01M | ||||
| Cash from Investing ActivitiesCash from Investing | -0.81M | -3.44M | -1.12M | -1.22M | -0.25M | -0.02M | -0.02M | -0.01M | ||||
| Financing Activities | ||||||||||||
| Debt Issuance and Repayment | ||||||||||||
| Long-Term Debt IssuancesLT Debt Issuance | 99.97M | |||||||||||
| Non-Current Debt | 99.97M | |||||||||||
| Net Debt Issuances and RepaymentsNet Debt Issuance | 99.97M | |||||||||||
| Change in Capital Stock | ||||||||||||
| Common Stock IssuedStock Issued | 200.02M | 1.09M | 38.73M | 32.95M | 0.35M | 1.25M | ||||||
| Net Shares Issued and RepurchasedNet Shares Issued | 200.02M | 1.09M | 38.73M | 32.95M | 0.35M | 1.25M | ||||||
| Net Equity Issued and RepurchasedNet Equity Issued | 200.02M | 1.09M | 38.73M | 32.95M | 0.35M | 1.25M | ||||||
| Other financing activitiesOther financing | -0.13M | |||||||||||
| Cash from Financing ActivitiesCash from Financing | 199.89M | 0.86M | 38.73M | 32.95M | 99.84M | 0.35M | 1.25M | |||||
| Additional items | ||||||||||||
| Change in Cash | 144.84M | -59.40M | -25.44M | -25.62M | -30.53M | -43.74M | 63.92M | -29.95M | -33.48M | -28.87M | ||
| Ending Cash Balance | 192.49M | 337.33M | 277.92M | 252.48M | 226.86M | 196.33M | 152.60M | 216.52M | 186.57M | 153.09M | 124.22M | 133.34M |
| Free Cash FlowFCF | -55.06M | -60.26M | -64.17M | -58.57M | -30.53M | -43.74M | -35.92M | -29.95M | -33.83M | -30.12M | ||
| Net Cash FlowNCF | 144.84M | -59.40M | -25.44M | -25.62M | -30.53M | -43.74M | 63.92M | -29.95M | -33.48M | -28.87M | ||
| Interest Paid | 6.89M | 4.61M | 1.30M | 2.54M | 2.54M | 2.51M | ||||||
| Income Taxes PaidTaxes Paid | 0.00M | 0.00M |
Pull Inhibrx Biosciences's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/statements?ticker=INBX&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/statements"
params = {"ticker": "INBX", "statement": "CF", "frequency": "Quarter", "period": "all", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/statements?ticker=INBX&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY");
const data = await res.json();